^
    Back
    Association details:
    Biomarker:IGFBP2 overexpression + PD-L1 overexpression
    Cancer:Melanoma
    Drug Class:PD1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    AACR-II 2020
    Title:

    Abstract 2159: IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma

    Published date:
    05/15/2020
    Excerpt:
    ...combined IGFBP2 and PD-L1 expression have the potential to predict the efficacy of anti-PD-1 treatment for malignant melanoma; because the combination of high IGFBP2 and PD-L1 expression characterizes melanoma patients with worse overall survival…
    DOI:
    10.1158/1538-7445.AM2020-2159